A Single Site, Phase 2B, Randomized, Double-Blind, Study to Assess the Efficacy, Safety, and Tolerability of Twice Daily Oral ALLOD-2 vs. Placebo in the Treatment of Chronic Low Back Pain (ANODYNE-4)
Phase of Trial: Phase II/III
Latest Information Update: 02 Nov 2017
At a glance
- Drugs ALLOD 2 (Primary)
- Indications Back pain
- Focus Registrational; Therapeutic Use
- Acronyms ANODYNE-4
- Sponsors Allodynic Therapeutics
- 29 Oct 2017 Planned number of patients changed from 48 to 12.
- 17 Aug 2017 Status changed from not yet recruiting to recruiting.
- 12 Aug 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Aug 2018.